Metastasis and Mortality in Men With Low- and Intermediate-Risk Prostate Cancer on Active Surveillance.

Active surveillance (AS) is a safe treatment option for men with low-risk, localized prostate cancer. However, the safety of AS for patients with intermediate-risk prostate cancer remains unclear. We identified men with NCCN-classified low-risk and favorable and unfavorable intermediate-risk prostate cancer diagnosed between 2001 and 2015 and initially managed with AS in the Veterans Health […]

Predictive Impact of Early Changes in Serum C-reactive Protein Levels in Nivolumab plus Ipilimumab Therapy for Metastatic Renal Cell Carcinoma – Beyond the Abstract

Nivolumab plus ipilimumab (NIVO-IPI) is one of the treatment standards for previously untreated clear cell renal cell carcinoma (RCC). Furthermore, the 20% progressive disease (PD) criterion as the best objective response was reportedly higher in the NIVO-IPI clinical trial than that in the other immune checkpoint inhibitor (ICI) combined regimens.1-4 There is an urgent need for […]

X